Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05683535
Other study ID # AELDA
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 19, 2018
Est. completion date January 9, 2023

Study information

Verified date April 2023
Source Scripps Health
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Progressive myopia can lead to severe vision loss and is associated with retinal detachment, glaucoma, and other comorbidities. Several studies have shown that off-label, low-dose atropine eye drops slow the progression of myopia. Many eye care providers are now prescribing off-label atropine eye drops for their myopic patients, with the prescribed concentrations varying amongst providers. The purpose of this study is to determine if low-dose atropine eyedrops used daily, cause adverse effects to the eyes. Patients currently using 0.01%, 0.03%, or 0.05% atropine eye drops obtained from compounding pharmacies will be assessed for associated adverse effects.


Description:

Eligibility: Myopic patients currently using 0.01%, 0.03%, or 0.05% atropine eye drops, prescribed by the investigator(s). Patients that meet the eligibility criteria will be given the parental consent form and child assent form (if applicable) during their regularly scheduled office visit. After consent forms are signed and at each follow-up visit, the investigator or study coordinator will begin by querying for adverse events by asking each patient general, non-directed questions, such as "How have you been feeling since the last visit?" Directed questioning and examination will then be done as appropriate. All reported adverse events will be documented on the appropriate CRF. The patients will then continue with their regular eye exam. Patients enrolled in the study will be assessed for adverse events at each regularly scheduled office visit for the duration of the study (up to 5 years), unless they choose to withdraw from the study. The study will assess 148 patients using either 0.01%, 0.03%, or 0.05% atropine eye drops (prescribed by the investigator), over a five-year period.


Recruitment information / eligibility

Status Completed
Enrollment 148
Est. completion date January 9, 2023
Est. primary completion date January 9, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - patients diagnosed with myopia - patients must be currently using 0.01%, 0.03%, or 0.05% atropine eye drops daily - low-dose atropine eye drops must be prescribed by the principal investigator and obtained from a compounding pharmacy Exclusion Criteria: - patients without myopia - patients with myopia, but not using low-dose atropine eye drops

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Atropine Sulfate
0.01%, 0.03%, or 0.05% atropine eye drops made from compounding pharmacies.

Locations

Country Name City State
United States Laura Kirkeby San Diego California

Sponsors (1)

Lead Sponsor Collaborator
Scripps Health

Country where clinical trial is conducted

United States, 

References & Publications (10)

Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, Tan D. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012 Feb;119(2):347-54. doi: 10.1016/j.ophtha.2011.07.031. Epub 2011 Oct 2. — View Citation

Chia A, Chua WH, Wen L, Fong A, Goon YY, Tan D. Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%. Am J Ophthalmol. 2014 Feb;157(2):451-457.e1. doi: 10.1016/j.ajo.2013.09.020. Epub 2013 Dec 4. — View Citation

Chia A, Lu QS, Tan D. Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2: Myopia Control with Atropine 0.01% Eyedrops. Ophthalmology. 2016 Feb;123(2):391-399. doi: 10.1016/j.ophtha.2015.07.004. Epub 2015 Aug 11. — View Citation

Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, Tan D. Atropine for the treatment of childhood myopia. Ophthalmology. 2006 Dec;113(12):2285-91. doi: 10.1016/j.ophtha.2006.05.062. Epub 2006 Sep 25. — View Citation

Fu A, Stapleton F, Wei L, Wang W, Zhao B, Watt K, Ji N, Lyu Y. Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression. Br J Ophthalmol. 2020 Nov;104(11):1535-1541. doi: 10.1136/bjophthalmol-2019-315440. Epub 2020 Feb 21. — View Citation

Gong Q, Janowski M, Luo M, Wei H, Chen B, Yang G, Liu L. Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis. JAMA Ophthalmol. 2017 Jun 1;135(6):624-630. doi: 10.1001/jamaophthalmol.2017.1091. — View Citation

Leo SW; Scientific Bureau of World Society of Paediatric Ophthalmology and Strabismus (WSPOS). Current approaches to myopia control. Curr Opin Ophthalmol. 2017 May;28(3):267-275. doi: 10.1097/ICU.0000000000000367. — View Citation

Pineles SL, Kraker RT, VanderVeen DK, Hutchinson AK, Galvin JA, Wilson LB, Lambert SR. Atropine for the Prevention of Myopia Progression in Children: A Report by the American Academy of Ophthalmology. Ophthalmology. 2017 Dec;124(12):1857-1866. doi: 10.1016/j.ophtha.2017.05.032. Epub 2017 Jun 29. — View Citation

Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, Ko ST, Young AL, Tham CC, Chen LJ, Pang CP. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology. 2019 Jan;126(1):113-124. doi: 10.1016/j.ophtha.2018.05.029. Epub 2018 Jul 6. — View Citation

Yam JC, Li FF, Zhang X, Tang SM, Yip BHK, Kam KW, Ko ST, Young AL, Tham CC, Chen LJ, Pang CP. Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 2 Report. Ophthalmology. 2020 Jul;127(7):910-919. doi: 10.1016/j.ophtha.2019.12.011. Epub 2019 Dec 21. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Summary of Source of Atropine Summary of name of compounding pharmacy, cost of eye drops, size of the bottle of eye drops, and if there was a delay in obtaining eye drops from the compounding pharmacy. up to 5 years
Other Summary of adverse events by starting dose Summary of adverse events by dose of atropine prescribed at start of study up to 5 years
Other Summary of demographics and medical history by atropine starting dose Summary of demographics and medical history by atropine starting dose up to 5 years
Primary Summary of adverse events by dose level at the time of the adverse event Summary of total adverse events and severity of adverse events, by dose level at time of the adverse event up to 5 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05919654 - Clinical Evaluation of MyoCare in Europe (CEME) N/A
Recruiting NCT03402100 - Eye Drops Study for Myopia Control in Schoolchildren N/A
Recruiting NCT03865160 - Low-dose Atropine for Myopia Control in Children Phase 2/Phase 3
Recruiting NCT06088225 - Myopia Preventing With Distance-image Screen N/A
Not yet recruiting NCT06085430 - Kubota Glass Parameter Refinement Study N/A
Not yet recruiting NCT06405711 - To Evaluate the Efficacy and Safety of an Defocus Lens in Slowing the Progression of Myopia N/A
Recruiting NCT05881655 - Slow Myopia Progression With Different Irradiance Light N/A
Recruiting NCT05761379 - Clinical Study of Light Therapy to Control Myopia Progression in Children N/A
Not yet recruiting NCT05760911 - Myopia Prevention Through Monitoring and Motivating Outdoor Activities With Smartwatches N/A
Recruiting NCT04722874 - Repeated Low-Level Red-Light Therapy and Orthokeratology in Fast-progressing Myopia Control N/A
Not yet recruiting NCT06221592 - Differences and Wearing Safety and Comfort of New Defocus Incorporated Multiple Segments Spectacle Lenses N/A
Completed NCT04806711 - Eleven Years of Menicon Z Night Contact Lens Wear in Reducing Myopia Progression in Children N/A
Completed NCT04806763 - Myopia Control With Orthokeratology Contact Lenses in Spain N/A
Completed NCT04806698 - Long-term Efficacy of Orthokeratology Contact Lens Wear in Controlling the Progression of Childhood Myopia N/A
Recruiting NCT05894382 - Double Helix Design Defocus Lens Spectacle (RACE) for Myopia Control N/A
Completed NCT05300321 - DIMS-myopia Progression ADN Axial Length Growth N/A
Withdrawn NCT03519490 - Can Distance Center and Near Center Multifocal Contact Lenses Control Myopia Progression in Children? N/A
Completed NCT05372991 - Safety, Tolerability and Pharmacodynamics Evaluation of CBT-009 Eye Drop Phase 1/Phase 2
Active, not recruiting NCT05373693 - Myopia-control Efficacy by Peripheral Defocus Lens (PDL) N/A
Completed NCT05007626 - Near Horizontal Heterophoria in Chinese Children